Crestline Management LP Acquires 47,452 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Crestline Management LP raised its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 88.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 101,035 shares of the company's stock after buying an additional 47,452 shares during the period. Crestline Management LP owned about 0.08% of Vaxcyte worth $8,271,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of PCVX. Wells Fargo & Company MN boosted its position in Vaxcyte by 53.7% in the fourth quarter. Wells Fargo & Company MN now owns 72,275 shares of the company's stock worth $5,916,000 after purchasing an additional 25,257 shares during the last quarter. Diversified Trust Co purchased a new position in shares of Vaxcyte during the 4th quarter valued at about $1,433,000. China Universal Asset Management Co. Ltd. increased its holdings in Vaxcyte by 23.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 26,428 shares of the company's stock worth $2,163,000 after acquiring an additional 4,962 shares in the last quarter. TimesSquare Capital Management LLC raised its stake in Vaxcyte by 53.7% during the 4th quarter. TimesSquare Capital Management LLC now owns 413,637 shares of the company's stock worth $33,860,000 after acquiring an additional 144,516 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its holdings in Vaxcyte by 70.8% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 593,523 shares of the company's stock valued at $49,418,000 after purchasing an additional 246,049 shares in the last quarter. 96.78% of the stock is owned by institutional investors.

Vaxcyte Trading Down 0.9 %

PCVX traded down $0.29 during trading hours on Friday, hitting $31.16. The company's stock had a trading volume of 2,030,375 shares, compared to its average volume of 1,306,324. Vaxcyte, Inc. has a 12 month low of $27.66 and a 12 month high of $121.06. The business's 50-day moving average price is $46.66 and its 200-day moving average price is $74.72. The stock has a market cap of $4.02 billion, a price-to-earnings ratio of -6.77 and a beta of 1.27.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($1.04) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). During the same quarter in the previous year, the company earned ($0.85) EPS. On average, analysts forecast that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Needham & Company LLC restated a "buy" rating and set a $90.00 price objective on shares of Vaxcyte in a research report on Tuesday, April 8th. Cantor Fitzgerald assumed coverage on Vaxcyte in a research note on Tuesday, April 22nd. They set an "overweight" rating on the stock. Guggenheim reissued a "buy" rating and issued a $160.00 price target on shares of Vaxcyte in a report on Wednesday, March 12th. The Goldman Sachs Group cut their price objective on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Finally, Bank of America lowered their target price on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $136.50.

Insider Transactions at Vaxcyte

In related news, COO Jim Wassil sold 8,000 shares of Vaxcyte stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $73.27, for a total transaction of $586,160.00. Following the completion of the transaction, the chief operating officer now directly owns 154,931 shares of the company's stock, valued at approximately $11,351,794.37. The trade was a 4.91 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 3.10% of the company's stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.